Background. Peripheral neuropathy is the dose-limiting toxicity of many oncology drugs,
including paclitaxel. There is large interindividual variability in the neuropathy, and several …

Background Peripheral neuropathy is the dose‐limiting toxicity of many oncology drugs,
including paclitaxel. There is large interindividual variability in the neuropathy, and several …

Peripheral neuropathy is a common side effect of many chemotherapeutic agents including
paclitaxel. We prospectively evaluated demographic and laboratory data in a cohort of 61 …

Purpose: Paclitaxel exposure, specifically the maximum concentration (C max) and amount
of time the concentration remains above 0.05 μmol/L (Tc> 0.05), has been associated with …

Aim: The aim of this study was to identify predictors for paclitaxel-induced peripheral
neuropathy (PIPN). Patients and Methods: We conducted a retrospective analysis of 227 …

e12503 Background: Peripheral neuropathy is a major dose-limiting side effect of paclitaxel
and can persist for up to two years after completing treatment, greatly affecting both the …

Background Paclitaxel treatment produces significant peripheral neuropathy, but the time
course of neuropathy development and outcomes are unclear. Dose reduction is the only …

Background: Paclitaxel is commonly used in combination regimens in patients with early
stage breast cancer, but its use is often limited by the development of severe paclitaxel …

e12031 Background: Peripheral neuropathy is the main dose-limiting complication of
paclitaxel. In this study, the association between clinical characteristics of the patients with …

OBJECTIVES/SPECIFIC AIMS: Peripheral neuropathy is the dose limiting toxicity of
paclitaxel treatment. Paclitaxel pharmacokinetics (PK), specifically the Cmax and amount of …